Imaging Synaptic Density in Aging and Alzheimer Disease with [18F]SynVesT-1 [0.03%]
使用[18F]SynVesT-1成像衰老和阿尔茨海默病中的突触密度
Joseph Giorgio,David N Soleimani-Meigooni,Mustafa Janabi et al.
Joseph Giorgio et al.
Synaptic density imaging with PET is a relatively new approach to monitoring synaptic injury in neurodegenerative diseases. However, there are remaining technical and clinical questions, including questions on reference region selection and...
Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy [0.03%]
[68Ga]Ga-成纤维细胞激活蛋白抑制剂-04与[18F]FDG PET成像在单一纤维瘤中的比较及FAP靶向放射药物治疗的初步应用
Rongxi Wang,Jiarou Wang,Jialin Xiang et al.
Rongxi Wang et al.
Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performan...
The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy [0.03%]
PSMA PET参数作为PSMA靶向放射药物治疗反应的生物标志物的作用
Vishnu Murthy,Vinicius Ludwig,Andrei Gafita et al.
Vishnu Murthy et al.
Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). 177Lu PSMA-targeted radiopharmaceutical therapy (RPT) enables direct delivery of β-radiatio...
Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics [0.03%]
[64Cu]Cu-NOTA-ABDB6的开发和临床前评估：具有改善药代动力学的CD70和白蛋白双重结合示踪剂
Xiaoyan Li,You Zhang,Jason C Mixdorf et al.
Xiaoyan Li et al.
CD70 is an emerging biomarker for both solid tumors and hematologic malignancies, highlighting the urgent need for a molecular imaging tracer capable of visualizing CD70 with favorable pharmacokinetics. Methods: ABDB6 was prepared by fusing...
Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria [0.03%]
神经系统疾病中血脑屏障外排转运体活性的成像：放射性示踪剂的选择标准
Nicolas Tournier,Oliver Langer
Nicolas Tournier
Efflux transporters of the adenosine triphosphate-binding cassette (ABC) superfamily, such as P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2), are highly expressed at the blood-brain barrier (BBB), where they c...
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists [0.03%]
放射药物治疗后的辐射安全指南：为非专业人员提出的流程和基本指导原则
Anna Mench,Celeste Winters,Erik Mittra et al.
Anna Mench et al.
With the increasing use of radiopharmaceutical therapies, there is a critical need to appropriately inform health care professionals (HCPs) who are unfamiliar with these therapies about the radiation safety precautions required when managin...
Siqi Li,Yasser G Abdelhafez,Lorenzo Nardo et al.
Siqi Li et al.
The standard Patlak plot, a simple yet efficient model, is widely used to describe irreversible tracer kinetics for dynamic PET imaging. Its widespread application to whole-body parametric imaging remains constrained because of the need for...
A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine [0.03%]
中国核医学学会2024年全国核医学调查结果简报
Jing Wang,Xiaoli Lan,Hongcheng Shi et al.
Jing Wang et al.
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial [0.03%]
卢PARP一期试验结果：177Lu-DOTATATE与PARP抑制剂Olaparib联合治疗生长抑素受体阳性肿瘤患者的可行性研究
Andreas Hallqvist,Elva Brynjarsdóttir,Tomas Krantz et al.
Andreas Hallqvist et al.
This phase I trial aimed to assess the feasibility and toxicity of combining the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib with 177Lu-DOTATATE in patients with somatostatin receptor-positive tumors, with the goal of e...